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Familial Mediterranean Fever (FMF) and COVID-19 show a remarkable overlap of
clinical symptoms and similar laboratory findings. Both are characterized by fever,
abdominal/chest pain, elevation of C-reactive protein, and leukocytosis. In addition,
colchicine and IL-1 inhibitors treatments that are effective in controlling inflammation
in FMF patients have recently been proposed for off-label use in COVID-19 patients.
Thus, FMF may resemble a milder recapitulation of the cytokine storm that is a hallmark
of COVID-19 patients progressing to severe disease. We analyzed the sequence of
the MEFV-encoded Pyrin protein – whose mutations cause FMF- in mammals, bats
and pangolin. Intriguingly, although Pyrin is extremely conserved in species that are
considered either a reservoir or intermediate hosts for SARS-CoV-2, some of the
most common FMF-causing variants in humans are present as wildtype residues in
these species. We propose that in humans, Pyrin may have evolved to fight highly
pathogenic infections.
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INTRODUCTION
The World Health Organization reported a novel coronavirus on December 30, 2019 as the cause
of a cluster of pneumonia cases in the city of Wuhan in the Hubei Province of China. Since
then, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected nearly 30
million individuals worldwide causing more than 900,000 deaths during the past 6 months of the
COVID-19 pandemic. Among European countries, Italy has been severely hit by COVID-19 (1).
Since the initial outbreak, a huge body of clinical and scientific information has been accumulated
on COVID-19, a multifaceted disease hitting not only lungs, but also other organs, with different
defined stages (2, 3). In most cases, SARS-CoV-2 enters the human body through inhaled droplets
and aerosols. Although contact with contaminated surfaces has been hypothesized as a second
possible infection route, the importance of this alternative mode of infection has not been assessed
systematically (4, 5). Upon infection, SARS-CoV-2 enters its target cells via: (a) binding of its spike
protein (S) to angiotensin converting enzyme 2 (ACE2); (b) activation through proteolysis of the
viral S protein catalyzed by the cellular transmembrane protease serine 2 (TMPRSS2); and (c) fusion
of SARS-CoV-2 virus with the host cell membrane. A wide variation in allele frequencies at ACE2
expressions single nucleotide polymorphisms (eSNPs) loci can partly explain the differences in
COVID-19 prevalence across different countries (6). Also, differential expression of ACE2 occurs
in several human cancers and chronic diseases, possibly influencing COVID-19 susceptibility and
severity (7). The involvement of ACE2 and TMPRSS2 in viral cell entry has been exploited to plan
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experimental therapies based on using protease inhibitors such
as camostat mesylate or nafamostat to block SARS-CoV-2
entry into cells (8, 9). Once inside the host cells, the SARS-
CoV-2 positive single stranded RNA (ssRNA) genome begins
replication and cytoplasmic accumulation. The ssRNA or its
double stranded intermediate (dsRNA) are recognized by the
innate immune nucleic acid sensing systems whose activation
exerts a first antiviral response through the production of
type 1 interferons and the secretion of pro-inflammatory
cytokines. The immunomodulation at this early stage of
infection might determine the growth of the viral load,
with most infected individuals still being asymptomatic or
paucisymptomatic, while almost 15% of SARS-CoV-2 positive
patients develop fever, coughing, occasionally ageusia and
anosmia and even gastrointestinal symptoms (3), with or without
hepatic involvement (10).
Patients progressing to the second phase show a strong
immunological and hyperinflammatory response that is defined
as a “cytokine storm” and which may lead to respiratory
worsening and bilateral pneumonitis. In this second stage,
COVID-19 patients manifest symptoms mimicking those present
in patients with auto-inflammatory diseases such as fever,
arthralgia, leucopenia and myocarditis (11–13).
THE PARALLEL WORLDS OF FMF AND
COVID-19
We were intrigued by the remarkable overlap between these
clinical manifestations and some of the typical manifestations
of Familial Mediterranean Fever (FMF), a largely recessively
inherited monogenic inflammasomopathy (autoinflammatory
disorder involving the inflammasome) caused by mutations
in the MEFV gene that is particularly prevalent in the
Mediterranean basin (14). While the previously mentioned
clinical signs are not specific to FMF and shared with other
hereditary recurrent fevers and inflammatory diseases, yet they
represent an indication of similarities among FMF pathogenesis
and the hyperinflammatory response observed in COVID-19
patients. Worthy of note, taste alteration has been reported
amongst the prodromal manifestations preceding fever attacks
in FMF (15, 16). We should stress that the cytokine storm
observed in the inflammatory stage of COVID19, has been
reported in other autoinflammatory diseases (AIDs) such as
the macrophage activation syndrome (MAS) and adult onset
Still’s disease (17). However, authors have often reported genetic
heterogeneity and overlap between these AIDs and hereditary
recurrent fevers (18–20).
Colchicine, a natural alkaloid from Colchicum autumnale, has
a long history as a drug to treat pain and swelling since ancient
Egypt. It is nowadays used to treat FMF, gout, Behçet syndrome
and recurrent non-infective pericarditis. Unsurprisingly, it is
currently being investigated in several COVID-19 therapeutic
trials (21–23). Notably, in colchicine-resistant or colchicine-
intolerant FMF patients, alternative treatments include biologics
that neutralize the pro-inflammatory cytokine interleukin (IL)-1β
directly (Canakinumab) or inhibit IL-1β-mediated activation of
the IL-1 Receptor (Anakinra and Rilonacept) (24–26). Similarly
to colchicine, several ongoing trials are evaluating the use of
IL-1 pathway inhibitors to treat COVID-19 patients (27–30).
Although first results from COVID-19 patients treated with these
repurposed drugs have been conflicting (31–33), the role of Pyrin
(the inflammasome sensor protein that is encoded by MEFV) in
modulating severity and outcome of COVID-19 is still unknown.
THE PYRIN INFLAMMASOME
The Pyrin domain architecture shows intriguing features which
may add insights into its possible role in COVID-19 disease.
Pyrin has a N-terminal pyrin domain (PYD) that is frequently
found in other innate immune pathogen sensors that mount
inflammasome responses such as NLRP1, NLRP3, and AIM2.
The N-terminal PYD domain engages in homotypic interactions
with its PYD counterpart in the adaptor protein apoptosis-
associated speck-like protein with a caspase recruitment domain
(ASC) to assemble ASC specks, which recruit the inflammatory
protease procaspase-1 inducing its self-cleavage and activation
(34). Caspase-1 in turn matures the proinflammatory cytokines
IL-1β and IL-18 and cleaves gasdermin D to trigger a lytic
cell death mode termed pyroptosis that promotes secretion
of aforementioned cytokines along with danger-associated
molecular patterns (DAMPs) such as IL-1alpha, HMGB1
and ATP (35).
Pyroptosis is a double-edged sword with both antiviral
and proviral activities during viral infections (36). In fact,
cell death can lead to halting viral replication and infection,
frequently at the price of increased inflammation. Conversely,
dead cells release a large number of viral particles contributing
to viral dissemination.
The MEFV encoded Pyrin sensor contains in its central region
three domains: a bZIP domain (aa 370-412), a B-box domain
(aa 370-412) and a coiled-coil domain (CC, aa 420-440). The
role of these three domains has not been thoroughly investigated
and few FMF-causing variants localize to Pyrin’s central region
(37). This region may have an autoinhibitory role precluding
the PYD domain from interacting with ASC and activating
pyroptosis (38). The C-terminal B30.2 (also known as PRY/SPRY)
domain is extremely important in FMF pathogenesis since most
of the disease-penetrant MEFV variants cluster in this region
(39). Although this uneven distribution of FMF-associated MEFV
mutations suggests that the B30.2 domain is crucial in regulating
Pyrin inflammasome activity, the precise molecular mechanisms
by which the B30.2 domain regulates FMF pathogenesis have not
been elucidated (40). Likely, FMF-causing mutations in the B30.2
domain may derail intramolecular interactions that keep Pyrin in
an autoinhibitory state.
THE CURIOUS FAMILY OF PYRIN
ORTHOLOGS
Interestingly, the degree of amino acid conservation along
the pyrin protein sequence is rather variable and may offer
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some insights in the dangerous liaisons between FMF and
COVID-19. We aligned the MEFV-encoded Pyrin amino
acid sequences from 19 different species including the only
pangolin and all bat species sequences available in GenBank
(Figure 1). Bats and pangolins have been considered the reservoir
and intermediate host, respectively, of SARS-CoV-2 before
transmission to humans.
The alignment of the Pyrin sequences presented unique
evolutionary features (Figure 1).
In fact, some of the most prevalent FMF-associated mutations
in human Pyrin were present as wild type in all bat species
analyzed and in pangolin (V726A, R761H). This resembles
previous findings that some FMF-associated mutations are
retrieved as wild type in primates, suggesting evolutionary
pressure on Pyrin (41). In contrast, other FMF-associated amino
acids residues that are largely prevalent in middle eastern
populations (M680I, M694I, M694V) were not observed in
bats and pangolin.
FIGURE 1 | Alignment of 19 MEFV orthologs from top to bottom as follow: Homo sapiens NP_000234.1, Mus musculus NP_001155263.1, Rattus norvegicus
XP_017452974.1, Rattus rattus XP_032769237.1, Bos taurus XP_015315767.1, Sus scrofa XP_013851182.1, Manis javanica XP_017515721.1, Pteropus
vampyrus XP_011374846.1, Pteropus alecto XP_006913958.1, Rousettus aegyptiacus XP_015977766.1, Rhinolophus ferrumequinum XP_032957625.1,
Desmodus rotundus XP_024409044.1, Phyllostomus discolor XP_028366066.1, Miniopterus natalensis XP_016066853.1, Hipposideros armiger XP_019488407.1,
Eptesicus fuscus XP_028001472.1, Myotis brandtii XP_014400628.1, Myotis davidii XP_015414020.1, Myotis lucifugus XP_023611041.1. The common names for
species analyzed are as follow: M. musculus (mouse), R. norvegicus (Norway or brown rat), R. rattus (black rat), B. taurus (cattle), S. scrofa (pig), M. javanica
(Malayan pangolin), P. vampyrus (Large flying fox), P. alecto (black flying fox), R. aegyptiacus (Egyptian rousettes or Egyptian fruit bat), R. ferrumequinum (greater
horseshoe bat), D. rotundus (common vampire bat), P. discolor (pale spear-nosed bat), M. natalensis (Natal long-fingered bat), H. armiger (great roundleaf bat),
E. fuscus (big brown bat), M. brandtii (Brandt’s bat), M. davidii (David’s myotis), M. lucifugus (little brown bat). Alignment were performed using the Cobalt software
(Papadopoulos JS and Agarwala R, Bioinformatics 23:1073-79, 2007 ). Boxes highlight the amino acid residues corresponding to common FMF-causing variants. In
green homo sapiens Pyrin, in blue pyrin from mammal species, in orange pangolin Pyrin, in red bats pyrin proteins.
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Worthy of note M680I, M694V, M694I, and R761H were
all associated with derailed Pyrin-induced IL-1β secretion in a
recently developed blood-based functional test for FMF alleles
(42). It is tempting to speculate that FMF patients carrying
V726A and R761H variants- which represents the wild type
residues in all bats and pangolin sequences- might modulate
better their cytokine response to SARS-CoV-2 infection. Further,
in a mouse knock-in model the V726A variant causes a
more severe FMF phenotype compared to M694V, M680I,
and elevated production of multiple cytokines (43). Given that
the M680I and M694V/I alleles in patients provoke a hyper-
inflammatory response not different from V726A and R761H
(at least in FMF), one may hypothesize that they could warrant
a comparable attenuation of viral infection. An elaboration on
this hypothesis would stem from the increased FMF severity
associated to M680I and M694V/I mutations. This raised level
of inflammation can either move the balance toward excess
inflammation in COVID-19 or be causing an even improved
immunomodulation in COVID-19 compared to V726A, R761H.
Moreover, historic pandemics and different pathogens may
have selected for different MEFV variants in their respective
host species and populations. Thus, a pathogen different from
coronaviruses (i.e., Yersinia pestis) might have selected the
M680I, M694V/I mutations in humans but not in bats. Indeed,
confirming this hypothesis, and shortly after the submission
of this work, genetic and experimental evidences have been
reported linking these MEFV variants with resistance to Yersinia
pestis (44, 45).
The E148Q and R202Q MEFV variants, which according
to a current consensus are considered neutral polymorphisms,
showed a response to colchicine challenge alike normal controls
(42). These two variants presented rather divergent evolutionary
features. While the glutamic acid at position 148 was strictly
conserved in all species analyzed, the arginine at position
202 was conserved in pangolin and in 7 of 13 bat species,
and changed to a glutamine in mouse and rats (Figure 2).
Therefore, E148Q and R202Q which appear to be neutral
in functional assays seem to be under apparently different
evolutionary pressures.
THE LESS THAN CASUAL WORLDWIDE
DISTRIBUTION OF PYRIN VARIANTS
The frequency of MEFV mutations and polymorphisms shows
a great variability in countries where FMF has a high
frequency. In fact, the M694V and M694I, are prevalent among
Turks, non-ashkhenazi Jews, and Arabs, while the M680I is
frequent in the Armenian population (46–49). The V726A and
R761H are generally associated with a milder phenotype, and
generally reported in clusters of FMF patients of Ashkhenazi
Jewish origin, and in the western Mediterranean area (50).
The E148Q variant, whose pathogenicity is still debated,
also presents a wide variation in frequency across different
populations (51).
This peculiar distribution of the MEFV variome led to the
hypothesis that the MEFV gene has been subjected to a balancing
selection and nucleotide variation, particularly in the B30.2
region, is adaptive (52). Thus, the severity of COVID-19 disease
in FMF patients, once infected, might be influenced, at least
partially, depending on specific MEFV genotypes which shows
country-specific differences.
The MEFV gene displays other intriguing evolutionary
features. In fact, while the N-terminal PYD domain is conserved
across all species, the B30.2 domain appears of more recent
origin. Of note, when considering the entire Pyrin amino acid
sequence, human Pyrin is more closely related to its bats and
pangolin homologs than to other mammal species (Figure 3).
In contrast, the human NLRP3 protein presented a high level
of homology in all analyzed species. It clustered with other
mammalian NLRP3 proteins in the phylogenetic tree and was
more distantly related to bat sequences (Figure 4).
In addition, differently from MEFV, the most common human
NLRP3 mutations- R260W, D303N, T348M, and L355P- which
represent more than 40% of the total mutation burden for this
gene (53, 54), were never present as wild type amino acid residues
in all bat species and pangolin (Figure 5).
Therefore, considering the Pyrin inflammasome a passive
bystander in SARS-CoV-2 infection could lead to overlooking an
important innate immune pathway that coordinates the response
to pathogens. In fact, inflammasome-driven pyroptosis is one
of the results of the cytokine storm which concurs to the high
pathogenicity of both SARS-CoV, and SARS-CoV-2 (55, 56).
THE ROLE OF THE NLRP3
INFLAMMASOME IN VIRAL INFECTIONS
Recent findings demonstrated that the SARS-CoV ORF3a protein
can provoke a cytokine storm by activation of the NLRP3
inflammasome through TRAF3-dependent ubiquitination of
ASC (57). A recent analysis of 2782 SARS-CoV-2 strains showed
that non-synonymous substitutions in the SARS-CoV-2 ORF3a
protein may alter virulence and infectivity (58). Additional viral
proteins are able to activate the NLRP3 inflammasome. The
NLRP3-mediated response to influenza A virus (IAV) has been
extensively studied and plays a crucial role in protecting the
host while helping in clearing the infection. However, if the
inflammatotory response is particularly prolonged and excessive
it can increase disease burden (59). The NLRP3 inflammasome
plays a critical role in guarding against IAV infection and
reducing lung damage consequent to infection (59, 60). Other
viruses are capable of activating the NLRP3 inflammasome. The
viroporin 2B, released upon human rhinovirus infection (HRV),
causes proteolytic activation of procaspase-1 and IL-1ß secretion
in a NLRP3 dependent manner (61). Several other viruses can
provoke a sustained response from the NLRP3 inflammasome
as extensively reviewed (62). Similarly to the MEFV-encoded
Pyrin, the N-terminal PYD domain of NLRP3 can recruit ASC
via homotypic interaction with its PYD counterpart on ASC
to assemble ASC filaments. The assembly of ASC filaments
in macromolecular structures known as ASC specks allow
the recruitment of procaspase-1 to induce its self-cleavage
and activation. Caspase-1 in turn cleaves the proinflammatory
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FIGURE 2 | Alignment of 19 Pyrin orthologs from amino acid 148 to amino acid 202 (human gene). Alignment order and color coding as in Figure 1.
FIGURE 3 | Phylogenetic tree of the Pyrin orthologs reconstructed from the COBALT multiple sequence alignment tool. The human Pyrin is boxed.
FIGURE 4 | Phylogenetic tree of the NLRP3 orthologs reconstructed from the COBALT multiple sequence alignment tool. The human NLRP3 protein is boxed.
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cytokines IL-1β/IL-18 and gasdermin D to trigger pyroptosis.
Thus, both Pyrin and NLRP3 inflammasomes may compete
for ASC binding and ASC oligomerization-dependent caspase-
1 activation.
AND THE ANSWER IS. . ..
Before the COVID-19 pandemic, a recent report (63)
demonstrated that bats, when infected with different zoonotic
FIGURE 5 | Alignment of 14 NLRP3 orthologs from amino acid 235 to amino acid 394 (human gene). The four residues whose mutations are responsible of more
than 40% of NLRP3 –associated autoinflammatory diseases are boxed.
FIGURE 6 | Proposed model of competitive binding to ASC of MEFV-encoded Pyrin and NLRP3. Abbreviations used: PYD, Pyrin domain, CARD, Caspase
recruitment domain, NACHT/NBD NACHT-, Nucleotide binding- domain, LRR, Leucine-rich repeats.
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viruses, can sustain high viral loads while presenting a dampened
NLRP3-mediated inflammatory response associated with a
decrease in both ASC speck formation and IL-1β secretion.
Hence, a dysregulation of the NLRP3 inflammasome can also
contribute to the utterly complex individual immune response to
viral infections (64). These findings suggest that the modulation
of innate immunity rather than an enhanced antiviral defense
might shape the different outcome of COVID-19 disease. Thus,
we hypothesize that competition between Pyrin and the NLRP3
inflammasomes for ASC recruitment may tilt the balance
between a cytokine storm and a finely adjusted protective
inflammation (Figure 6).
FMF, in which Pyrin activity and consequent ASC
oligomerization are increased because of MEFV pathogenic
variants, may therefore represent a unique opportunity as a
disease model to investigate the regulation of the inflammatory
response to novel emerging viruses. We presented here
the unique evolutionary features of the MEFV-encoded
Pyrin suggesting its putative contribution in shaping the
individual risk to develop severe complications consequent to
infectious diseases.
Several factors could have contributed to the rapid spreading
of COVID-19 pandemic, including access to adequate health
care, aging demographic, metabolic dysfunctions, socio-cultural
differences. It would be wise not to discard individual genetics,
including the MEFV gene, from the mix.
Future investigation on how carriers of different MEFV
genotypes have responded to coronavirus infections could help
in refining existing and novel therapeutics in development for
present and future challenges. In conclusion, the answer to the
title question might not be blowing in the wind but could
hopefully be found in a deeper knowledge of inflammasome
regulation in well-known inflammatory diseases.
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